Investments
20Portfolio Exits
2Partners & Customers
1
Want to inform investors similar to Nan Fung Life Sciences about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Latest Nan Fung Life Sciences News
May 23, 2022
<img alt="Bisnow/Ellie Meyer Outshine Properties' Bill Hunter, New York Economic Development Corp.'s Susan Rosenthal, Hunter Roberts Construction Group's Brian Aronne, Nan Fung Life Sciences' Matt Powers and SGA's Brooks Slocum." border="0" height="170" src="https://www.biohealthinnovation.org//images/dmvgadmin/the_real_estate_problem_holding_back_nyc_s_life_sciences_industry.png" style="float: right;" title="The_Real_Estate_Problem_Holding_Back_NYC_s_Life_Sciences_Industry.png" width="249" />Life sciences in New York City is poised for growth, but industry leaders said that will only be assured if developers build enough spaces for startups of all sizes. Unless the city can accommodate life sciences companies in their earlier years, when they need less space, experts warn NYC could lose talent to rival life sciences hubs. Image: Bisnow/Ellie MeyerOutshine Properties' Bill Hunter, New York Economic Development Corp.'s Susan Rosenthal, Hunter Roberts Construction Group's Brian Aronne, Nan Fung Life Sciences' Matt Powers and SGA's Brooks Slocum.
Nan Fung Life Sciences Investments
20 Investments
Nan Fung Life Sciences has made 20 investments. Their latest investment was in Ablaze Pharmaceuticals as part of their Series A on November 11, 2021.
Nan Fung Life Sciences Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
11/29/2021 | Series A | Ablaze Pharmaceuticals | $75M | Yes | 12 | |
11/18/2021 | Series A - III | Fountain Therapeutics | $15M | No | 8 | |
8/3/2021 | Series A - II | Engrail Therapeutics | $32M | No | 15 | |
5/5/2021 | Series C | |||||
3/10/2021 | Series B |
Date | 11/29/2021 | 11/18/2021 | 8/3/2021 | 5/5/2021 | 3/10/2021 |
|---|---|---|---|---|---|
Round | Series A | Series A - III | Series A - II | Series C | Series B |
Company | Ablaze Pharmaceuticals | Fountain Therapeutics | Engrail Therapeutics | ||
Amount | $75M | $15M | $32M | ||
New? | Yes | No | No | ||
Co-Investors | |||||
Sources | 12 | 8 | 15 |
Nan Fung Life Sciences Portfolio Exits
2 Portfolio Exits
Nan Fung Life Sciences has 2 portfolio exits. Their latest portfolio exit was Oculis on October 17, 2022.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
10/17/2022 | Acq - Pending | 1 | |||
Date | 10/17/2022 | |
|---|---|---|
Exit | Acq - Pending | |
Companies | ||
Valuation | ||
Acquirer | ||
Sources | 1 |
Nan Fung Life Sciences Partners & Customers
1 Partners and customers
Nan Fung Life Sciences has 1 strategic partners and customers. Nan Fung Life Sciences recently partnered with Celltrion on July 7, 2019.
Date | Type | Business Partner | Country | News Snippet | Sources |
|---|---|---|---|---|---|
7/22/2019 | Partner | South Korea | Leveraging on Nan Fung Group 's strong capital base and long term commitment to the area , Nan Fung Life Sciences aims to become the ideal partner for scientists , entrepreneurs , corporations and investors in the life science space . | 1 |
Date | 7/22/2019 |
|---|---|
Type | Partner |
Business Partner | |
Country | South Korea |
News Snippet | Leveraging on Nan Fung Group 's strong capital base and long term commitment to the area , Nan Fung Life Sciences aims to become the ideal partner for scientists , entrepreneurs , corporations and investors in the life science space . |
Sources | 1 |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.